KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-cash Items (2016 - 2017)

BeOne Medicines (ONC) reported Non-cash Items of $32.5 million for Q4 2017, down 40.83% year-over-year from $54.9 million in Q4 2016, and down 40.83% on a QoQ basis from $54.9 million in Q4 2016.

BeOne Medicines (ONC) has 2 years of Non-cash Items data on file, last reported at $32.5 million in Q4 2017.

  • Quarterly Non-cash Items fell 40.83% year-over-year to $32.5 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $32.5 million (down 40.83% YoY) and the FY2017 annual result came in at $32.5 million, down 40.83% from the prior year.
  • Non-cash Items fell to $32.5 million in Q4 2017 per ONC's latest filing, from $54.9 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $54.9 million in Q4 2016 and bottomed at $32.5 million in Q4 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 BeOne Medicines - - 1.35 Bn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2017 32.50 Mn
Dec 31, 2017 32.50 Mn
Dec 31, 2016 54.94 Mn
Dec 31, 2016 54.94 Mn